Follow us...

 

Search News Archives

News Channels

 

New Laboratory Products

Lab News

Research & Case Studies

Microscopy | Image Analysis

Separation Science

Brochures & Literature

Videos

Events | Webinars

 

 

Conferences | Events

Horizon Discovery Announces Progress of its Gene and Cell Therapy Platform for Contract Service and Therapeutic Applications

publication date: Aug 1, 2017
 | 
author/source: Horizon Discovery Group

Horizon Discovery Group plc (LSE: HZD), the world leader in the application of gene editing technologies, announces progress of its gene and cell therapy platform for contract service and therapeutic applications.

horizonThe new offering will make use of Horizon’s extensive suite of gene editing technologies, including CRISPR and its proprietary rAAV and Transposon technologies, to edit pluripotent stem cells (iPSC) and primary human lymphocytes.

Horizon is already working with three clients to support preclinical development across a variety of gene and cell therapy treatments in areas of high unmet medical need. This work is expected to contribute more than $2 million in revenue in 2017.

In addition, Horizon’s research biotech business is looking to exploit its unique IP and expertise to develop a universal cell therapy platform to support companies focused on developing autologous and allogeneic (“off the shelf”) cell therapy projects in areas of high unmet medical need. These include immuno-oncology, autoimmune diseases, rare genetic diseases, metabolic, neurological and blood disorders.

Dr Darrin M Disley, Chief Executive Officer, Horizon Discovery Group, commented: “Horizon is a world leader in gene editing, and our deep expertise combined with our suite of proprietary technologies makes us the perfect “go-to” partner for companies targeting gene and cell therapies across a range of diseases. The use of genetic screening approaches for novel target identification and precision gene editing for the subsequent development of gene and cell therapies are areas of burgeoning interest in biotech and pharma. Repairing the direct causes of genetic diseases, either at the DNA or cellular level will enable the personalised treatment of diseases at a lower cost and with better therapeutic results.”


more about horizon discovery group


 



 

 

Popular this Month...

Our Top 10 most popular articles this month

 

Today's Picks...

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd

 


Promotions

 

Media Partners